However, a secondary endpoint study of the adjuvant denosumab and aromatase inhibitor therapies suggests that targeting the PTHrP-driven pathway can delay metastatic disease in breast cancer patients and result in a significant though small (87.2% to 89%) increase in disease-free survival, although the study lacks the appropriate power to determine the therapeutic potential of denosumab [35]. Here, PTHLH is linked to breast cancer.